Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

94.5% effectiveness from Moderna’s COVID-19 vaccine

94.5% effectiveness from Moderna’s COVID-19 vaccine

Moderna’s potential COVID-19 vaccine allegedly is more effective than Pfizer’s

It seems like the international markets have a new reason to rally. If last week Pfizer’s vaccine proved to be 90% efficient in preventing COVID-19 infection, Moderna’s experimental vaccine seems to top that percentage.

Moderna stated that its potential COVID-19 cure showed 94.5% effectiveness in preventing infection according to data from a late-stage clinical trial. So far, it is the second American company to report over the top results in a week.

The company expects to gather enough safety data to file for emergency use authorization (EUA) in the upcoming weeks. If everything goes smoothly, the US could have two viable COVID-19 vaccines by the end of the year. If both Pfizer and Moderna receive the EUA in December, the US could have available roughly 60 million doses of vaccine.

While the abovementioned companies are looking for EUA, Johnson & Johnson just launched a large-scale late-trial for its potential COVID-19 drug. The trial consists of administering two vaccine doses and run it up simultaneously with a trial that involves only one dose. The recruitment of volunteers will end in March 2021, and the trial will last one year.

After the announcement, Moderna stock price went up more than 9.1%, while USA500 gained 1.3%.

Read here all about Pfizer’s potential COVID-19 vaccine!

Sources: reuters.com, finance.yahoo.com

Maklumat yang disediakan oleh za.capex.com bukan berbentuk tawaran atau permintaan untuk tujuan pembelian atau penjualan apa-apa produk kewangan yang disebutkan di sini atau melibatkan perundngan, atau nasihat mahupun cadangan berkenaan dengan kewangan produk tersebut.

Maklumat ini disediakan untuk edaran umum. Ia tidak mengambil kira objektif pelaburan tertentu, keadaan kewangan atau keperluan tertentu dari mana-mana penerima.

Anda harus bebas menilai setiap produk kewangan dan mempertimbangkan kesesuaian produk kewangan sedemikian, dengan mengambil kira objektif pelaburan tertentu anda, keadaan kewangan atau keperluan khusus, dan berunding dengan penasihat kewangan bebas, sebelum berurusan dalam produk kewangan yang disebutkan dalam dokumen ini.

Maklumat ini tidak boleh diterbitkan, diedar semula, diterbitkan semula atau diedarkan secara keseluruhan atau sebahagian kepada mana-mana individu lain tanpa kebenaran bertulis daripada Syarikat terlebih dahulu.

Prestasi lalu tidak sentiasa menggambarkan prestasi atau kemungkinan masa depan. Sebarang pandangan atau pendapat yang dikemukakan hanyalah pandangan penulis semata-mata dan tidak mewakili za.capex.com